InvestSMART

Vectus Biosystems Limited (ASX:VBS)

ALERT: Price-sensitive ASX Announcement for VBS
Current share price for VBS : $0.115 -0.025 (-17.86%)+
Announcement
Release
26 Feb 2026 12:25PM
Price at Release
$0.140
Full Release
download
Summary
Vectus Biosystems Limited's Half Year Report for the period ending 31 December 2025 highlights ongoing financial challenges and strategic developments. The company reported a net loss of $731,694, down from the previous period, and a decrease in operating expenses to $0.7 million from $1.5 million. Vectus is focused on the commercialisation of its lead drug VB0004, which has shown promise in treating fibrosis-related diseases. A significant development was the signing of a binding term sheet with XORTX Therapeutics Inc. for the sale of their VB4-P5 compound, expected to provide additional capital liquidity. The report outlines efforts to secure partnerships to ensure the company's financial viability amidst ongoing losses and discusses potential funding through the sale of XORTX shares post-transaction. The company's strategic direction remains on developing and commercialising its drug library, particularly focusing on fibrosis treatments.
Key Points
  • Net loss of $731,694 reported for the half-year.
  • Focus on commercialising VB0004 drug.
  • Binding term sheet signed with XORTX Therapeutics Inc. for VB4-P5 compound sale.
  • Operating expenses reduced to $0.7 million from $1.5 million.
  • Potential for additional liquidity from XORTX shares.
  • Company focused on partnerships to improve financial status.
  • No dividends were declared or paid.
  • Ongoing strategic discussions for commercialisation and funding.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should refer to the full announcement here for further information.